Colchicine also a winner of @escardio 2020
This study was building on COLCOT results in secondary prevention in patients w/ chronic CAD
🔺5522 patients enrolled
🔺Randomized to Colchicine 0.5 mg vs Placebo
🔺Excluded advanced CKD, HF, valve ds
![](https://pbs.twimg.com/media/Egv40gvXcAEQbNL.jpg)
![](https://pbs.twimg.com/media/Egv40gvWAAAftrp.jpg)
![](https://pbs.twimg.com/media/Egv40gxXYAEhSmy.jpg)
![](https://pbs.twimg.com/media/Egv40gwXcAEwVnO.jpg)
🔺90% of patients tolerated medication
🔺Mostly men (84%)
🔺Most had prior revascularization
🔺 Most well treated
![](https://pbs.twimg.com/media/Egv5pLnWsAEbcEu.jpg)
![](https://pbs.twimg.com/media/Egv5pLoXkAAOXBD.jpg)
![](https://pbs.twimg.com/media/Egv5pLoXYAAVFxk.jpg)
![](https://pbs.twimg.com/media/Egv5pLmXcAABOpS.jpg)
♥️30% reduction in treatment arm for Primary Outcome
♥️28% ⤵️ in MACE
♥️subgroup analysis shown
#ESCCongress #residualrisk #colchicine #inflammation
![](https://pbs.twimg.com/media/Egv6NOFWkAAaHF8.jpg)
![](https://pbs.twimg.com/media/Egv6NOMX0AQ7UDg.jpg)
![](https://pbs.twimg.com/media/Egv6NOLWsAI6Edz.jpg)
![](https://pbs.twimg.com/media/Egv65PpXcAIPMx_.jpg)
🔺Impressively well-tolerated drug in this cohort; no differences in SAE vs. placebo
🔺Findings summarized here but in Chronic CAD colchicine may reduce residual risk
🔺Is it time now to add this in with our patients we manage for secondary prevention?
![](https://pbs.twimg.com/media/Egv7TR-XgAE5xdc.jpg)
![](https://pbs.twimg.com/media/Egv7TSEXsAMTmWM.jpg)
![](https://pbs.twimg.com/media/Egv7TSFX0AIjiE8.jpg)
♥️Need to understand can interact with statins when we use colchicine
♥️need to monitor blood test when on this
♥️ May become part of secondary prevention to reduce residual risk
![](https://pbs.twimg.com/media/Egv8GqkWsAANbEd.jpg)